Table 1.
Patient characteristics
| Age (years) | |
| Median | 51.0 |
| Range | 28.0–85.3 |
| Gender | |
| Male | 9 (43) |
| Female | 12 (57) |
| KPS | |
| 90–100 | 9 (43) |
| 80 | 10 (48) |
| 70 | 2 (10) |
| Histology | |
| Benign (WHO grade I) | 8 (38) |
| Atypical (WHO grade II) | 9 (43) |
| Anaplastic (WHO grade III) | 4 (19) |
| Time from Dx (years) | |
| Median | 6.33 |
| Range | 1.21–23.94 |
| Prior treatment | |
| Surgery only | 9 (43) |
| XRT (conformal) | 7 (33) |
| SRS | 7 (33) |
| Chemotherapy | 2 (10) |
| EIAED | |
| Yes | 3 (14) |
| No | 18 (86) |
| Neurofibromatosis | |
| Yes | 1 (5) |
| No | 20 (95) |
| Number lesions | |
| 1 | 8 (38) |
| 2–3 | 7 (33) |
| 4–6 | 4 (19) |
| > 6 | 2 (10) |
| Number prior PD | |
| 1 | 4 (19) |
| 2 | 10 (48) |
| 3 | 4 (19) |
| ≥4 | 3 (14) |
PD progressive disease, EIAED CYP3A enzyme inducing anti-epileptic drugs, SRS stereotactic radiosurgery, XRT external beam radiotherapy, Dx diagnoses, KPS Karnofsky performance status